ArticleCancers2011
New Approaches to Immunotherapy for HPV Associated Cancers.
Article in Cancers, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 42 citations in OpenAlex.
- The interplay between HPV, vaginal microbiota and host immunity in cervical carcinogenesis.Discover oncology · 2026Review
- Current and future direction in treatment of HPV-related cervical disease.Journal of molecular medicine (Berlin, Germany) · 2022Review
- Infiltration Patterns of Cervical Epithelial Microenvironment Cells During Carcinogenesis.Frontiers in immunology · 2022Review
- Role of Immunity and Vaginal Microbiome in Clearance and Persistence of Human Papillomavirus Infection.Frontiers in cellular and infection microbiology · 2022Review
- Characterization of recombinant gorilla adenovirus HPV therapeutic vaccine PRGN-2009.JCI insight · 2021Article
- HPV Involvement in the Tumor Microenvironment and Immune Treatment in Head and Neck Squamous Cell Carcinomas.Cancers · 2020Review
- Article
- Activities of stromal and immune cells in HPV-related cancers.Journal of experimental & clinical cancer research : CR · 2018Review
- hrHPV E5 oncoprotein: immune evasion and related immunotherapies.Journal of experimental & clinical cancer research : CR · 2017Review
- Perspectives for therapeutic HPV vaccine development.Journal of biomedical science · 2016Review
- Current state in the development of candidate therapeutic HPV vaccines.Expert review of vaccines · 2016Review
- A Platform for Designing Genome-Based Personalized Immunotherapy or Vaccine against Cancer.PloS one · 2016Article
- Tracking vaginal, anal and oral infection in a mouse papillomavirus infection model.The Journal of general virology · 2015Article
- Unique potential of 4-1BB agonist antibody to promote durable regression of HPV+ tumors when combined with an E6/E7 peptide vaccine.Proceedings of the National Academy of Sciences of the United States of America · 2015Article
- Attenuated Recombinant Influenza A Virus Expressing HPV16 E6 and E7 as a Novel Therapeutic Vaccine Approach.PloS one · 2015Article
- A shifting paradigm in the aetiology of oral and pharyngeal cancer in Sri Lanka: a case-control study providing serologic evidence for the role of oncogenic HPV types 16 and 18.Infectious agents and cancer · 2015Article
- HPV16-E7 expression in squamous epithelium creates a local immune suppressive environment via CCL2- and CCL5- mediated recruitment of mast cells.PLoS pathogens · 2014Article
- Depletion of tumor-associated macrophages enhances the anti-tumor immunity induced by a Toll-like receptor agonist-conjugated peptide.Human vaccines & immunotherapeutics · 2014Article
- Targeted treatments for cervical cancer: a review.OncoTargets and therapy · 2012Article
- Clinical and Dermoscopic Study of Intra-lesional Injection of Acyclovir Versus Candida Antigen in Treatment of Plantar Warts.Indian journal of dermatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cervical cancer is the second most common cancer of women worldwide and is the first cancer shown to be entirely induced by a virus, the human papillomavirus (HPV, major oncogenic genotypes HPV-16 and -18). Two recently developed prophylactic cervical cancer vaccines, using virus-like particles (VLP) technology, have the potential to prevent a large proportion of cervical cancer associated with HPV infection and to ensure long-term protection. However, prophylactic HPV vaccines do not have therapeutic effects against pre-existing HPV infections and do not prevent their progression to HPV-associated malignancy. In animal models, therapeutic vaccines for persisting HPV infection can eliminate transplantable tumors expressing HPV antigens, but are of limited efficacy in inducing rejection of skin grafts expressing the same antigens. In humans, clinical trials have reported successful immunotherapy of HPV lesions, providing hope and further interest. This review discusses possible new approaches to immunotherapy for HPV associated cancer, based on recent advances in our knowledge of the immunobiology of HPV infection, of epithelial immunology and of immunoregulation, with a brief overview on previous and current HPV vaccine clinical trials.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.